Exploring the connection between hidradenitis suppurativa and erythema nodosum: a case report


Submitted: 10 October 2023
Accepted: 3 December 2023
Published: 8 February 2024
Abstract Views: 508
PDF: 249
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Erythema nodosum (EN) is inflammation of subcutaneous fat. Etiologies include autoimmune diseases, drugs, infections, pregnancy, malignancy, and idiopathic origins. A 37-year-old female with a history of recurrent cellulitis and type II diabetes presented with worsening swollen lumps on upper extremities for four months during a Hurley Stage III hidradenitis suppurativa (HS) flare. Exam revealed multiple erythematous pustules and warm indurated nodules over diffuse edema on the upper extremities. Lesions were refractory to trimethoprim/sulfamethoxazole, cefalexin, clindamycin, and levofloxacin. Routine blood labs, ESR, and ANA were unremarkable. EN was diagnosed. Trimethoprim/sulfamethoxazole, saturated solution potassium iodide (SSKI), and ibuprofen were prescribed. At the three-week follow-up, EN completely resolved the issue except for one lesion. Literature review revealed one case of EN manifestation in association with HS but was complicated by Beçhet’s syndrome. We propose HS as an underlying cause of EN and SSKI an effective treatment for EN and HS.


Leung AKC, Leong KF, Lam JM, Erythema nodosum. World J Pediatr 2018;14:548-54.

Perez-Garza DM, Chavez-Alvarez S, Ocampo-Candiani J, Gomez-Flores M. Erythema Nodosum: A Practical Approach and Diagnostic Algorithm. Am J Clin Dermatol 2021;22:367-78.

Schwartz RA, Nervi SJ. Erythema nodosum: a sign of systemic disease. Am Fam Physician 2007;75:695-700.

Scheinfeld N. Diseases associated with hidranitis suppurativa: part 2 of a series on hidradenitis. Dermatol Online J 2013;19:18558.

Kurzen H, Kurokawa I, Jemec JBE, et al. What causes hidradenitis suppurativa? Exp Dermatol 2008;17:455-72.

Cartron A, Driscoll MS. Comorbidities of hidradenitis suppurativa: A review of the literature. Int J Womens Dermatol 2019;5:330-4.

Shalom G, Freud T, Harman-Boehm I, et al. Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol 2015;173:464-70.

Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2010;2:9-16.

Scala E, Cacciapuoti S, Garzorz-Stark N, et al. Hidradenitis Suppurativa: Where We Are and Where We Are Going. Cells 2021;10.

Guet-Revillet H, Coignard-Biehler H, Jais JP, et al. Bacterial pathogens associated with hidradenitis suppurativa, France. Emerg Infect Dis 2014;20:1990-8.

Hayashi S, Ishikawa S, Ishii E, et al. Anti-Inflammatory Effects of Potassium Iodide on SDS-Induced Murine Skin Inflammation. J Invest Dermatol 2020;140:2001-8.

Hanson, M., Maloney, M. E., & Kuchnir, L. (2024). Exploring the connection between hidradenitis suppurativa and erythema nodosum: a case report. Dermatology Reports, 16(4). https://doi.org/10.4081/dr.2024.9866

Downloads

Download data is not yet available.

Citations